Table 1

Characteristics of new statin users over time

Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Number of new statin users595657.8%905657.6%10 92452.4%10 25345.9%12 17847.0%13 53544.4%15 23342.7%16 49940.3%17 50937.8%17 75535.0%
All statin users10 299100.0%15 724100.0%20 848100.0%22 317100.0%25 924100.0%30 491100.0%35 674100.0%40 989100.0%46 323100.0%50 687100.0%
Sex:
  F323254.3%492554.4%591354.1%552353.9%639152.5%718053.0%804352.8%851951.6%918552.5%927852.3%
 M272445.7%413145.6%501145.9%473046.1%578747.5%635547.0%719047.2%798048.4%832447.5%847747.7%
Age: mean (SD)58.41(11.84)58.22(12.19)57.98(12.40)58.44(12.45)59.01(12.51)59.13(12.45)59.35(12.59)59.28(12.68)59.77(12.73)59.76(12.70)
Indication and comorbidities
 Dyslipidemia (indication)445774.8%681575.3%835776.5%784476.5%935276.8%10 28176.0%11 59476.1%12 65576.7%13 43176.7%13 72377.3%
 Hypertension356459.8%521457.6%619256.7%600558.6%729059.9%803159.3%912259.9%985959.8%10 72661.3%10 81660.9%
 Diabetes209235.1%316835.0%363233.2%363935.5%433635.6%489736.2%537835.3%601136.4%641236.6%626235.3%
 IHD156126.2%226625.0%253023.2%243123.7%285123.4%307822.7%335722.0%351321.3%368021.0%353619.9%
 Heart failure2173.6%3263.6%3673.4%3843.7%4623.8%4863.6%5623.7%5903.6%6443.7%6373.6%
 Afib360.6%690.8%740.7%910.9%1201.0%1411.0%1731.1%2201.3%1881.1%2391.3%
 CeVD74912.6%112112.4%124511.4%121611.9%147212.1%162612.0%182212.0%187911.4%209011.9%201911.4%
 PVD2283.8%3443.8%4143.8%3773.7%4783.9%4553.4%5663.7%5913.6%6713.8%6543.7%
 CKD3846.4%4975.5%5404.9%5215.1%6085.0%6895.1%7775.1%8395.1%8785.0%10275.8%
 CLD130121.8%186720.6%210719.3%198419.4%214217.6%228816.9%240915.8%258515.7%275815.8%268915.1%
 COPD5769.7%8179.0%9778.9%8718.5%9197.5%9967.4%10176.7%11066.7%11416.5%10656.0%
 Dementia490.8%720.8%820.8%830.8%1100.9%1581.2%1991.3%2261.4%3151.8%2981.7%
 Malignancy1652.8%2552.8%3253.0%3053.0%3973.3%4793.5%5463.6%6554.0%7024.0%7524.2%
  • Unit: number of patient.

  • Afib, atrial fibrillation; CeVD, cerebrovascular diseases; CKD, chronic kidney diseases; CLD, chronic liver diseases; COPD, chronic obstructive pulmonary disease; IHD, ischaemic heart disease; PVD, peripheral vascular diseases.